Tekla Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Tekla Capital Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-438,623	Closed	-$6.13M	–	133
2015 Q1	$6.13M	Hold	438,623	–	–	0.24%	74
2014 Q4	$7.41M	Sell	438,623 -242,123	-36%	-$3.53M	0.35%	62
2014 Q3	$9.14M	Hold	680,746	–	–	0.43%	48
2014 Q2	$8.67M	Buy	680,746 +330,847	+95%	+$3.45M	0.8%	37
2014 Q1	$4.16M	Hold	349,899	–	–	0.42%	45
2013 Q4	$4.83M	Hold	349,899	–	–	0.51%	38
2013 Q3	$6.11M	Buy	+349,899	New	+$6.7M	0.68%	37

Other funds holding INFI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tekla Capital Management's INFI Position: Q2 2015 in Review

Tekla Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2015, closing a stake of 438,623 shares — an estimated $6.13M sold.

Tekla Capital Management first reported a position in INFI in Q3 2013 and held it in 7 quarters. The position peaked at $9.14M in Q3 2014. 137 funds tracked by Wall St. Rank hold INFI as of Q2 2015.

Tekla Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Tekla Capital Management sold 438,623 Infinity Pharmaceuticals, Inc. shares in Q2 2015, an estimated $6.13M.
Tekla Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2013 and held it in 7 quarters.
Tekla Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $9.14M in Q3 2014.
137 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2015.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.